Alzheimers Disease Biomarkers in Cerebrospinal Fluid and Blood, 2011 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Alzheimers Disease Biomarkers in Cerebrospinal Fluid and Blood, 2011

Description:

Aarkstore.com announce a new report ""Alzheimers Disease Biomarkers in Cerebrospinal Fluid and Blood, 2011 through its vast collection of market research report. – PowerPoint PPT presentation

Number of Views:149

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Alzheimers Disease Biomarkers in Cerebrospinal Fluid and Blood, 2011


1
Aarkstore.com Alzheimers Disease Biomarkers in
Cerebrospinal Fluid and Blood, 2011
2
Summary
  • This report provides an overview of biomarkers
    associated with Alzheimers disease (AD) found in
    cerebrospinal fluid and blood, that have
    potential in differential diagnosis, in following
    treatment, in clinical trials and drug discovery.
    AD biomarkers offer utility in a number of
    ways identification of groups at risk of
    developing AD early detection of AD
    differentiation of different forms of
    neurodegenerative disease from AD, as well as
    developmental stages (such as MCI), thought to
    progress to AD supporting specific treatments or
    pharmacological interventions following the
    time-course progression of AD and response to
    therapy assessing patient prognosis advancing
    understanding of the disease, including risk
    factors, and the changes that precede its
    development the identification of new drug
    targets and candidate molecules development of
    discovery assays for efficacy or toxicity
    markers and supporting the recruitment of
    subjects most likely to provide a meaningful
    analysis of treatment effects. These areas are,
    therefore, considered and discussed in relation
    to the AD biomarkers presented in this report.
    Of the biomarker areas being researched, the
    goal of developing methods for the early
    detection of AD, including the prediction of risk
    in particular patient groups, is a key priority.
    It is believed that the first symptoms of AD
    generally diagnosed using cognitive, behavioural
    and functional assessments occur after
    significant neuronal loss has already occurred.

3
Table of Contents
  • Index Page Chapter 1 Background 18 1.
    Alzheimers Disease 19 1.1 Statistics and Costs
    19 1.2 Histopathology 20 1.3 Amyloid Beta
    (Abeta) 20 1.4 Tau Proteins and Neurofibrillary
    Tangles 21 1.5 Cholinergic Hypothesis 22 1.6
    Diagnosis 22 1.7 Cognitive Tests 23 1.8 Stages
    of Alzheimers Disease 25 1.9 Treatment of AD 25
    1.10 Biomarkers 26 1.11 Genetics 27 Chapter 2
    CSF Biomarkers and Diagnosis 33-47 Chapter 3
    Blood Biomarkers and Diagnosis 52-62 Chapter 4
    CSF Biomarkers and Early Detection 65-75 Chapter
    5 Blood Biomarkers and Early Detection 74-80
    Chapter 6 Discussion 83-89

4
More Related Reports
  •   VEGF Inhibition Therapy-Indicating and
    Prognostic Biomarkers, 2011
  •   Biomarkers in Alzheimers Disease, 2011
  •   Alzheimers Disease Autoantibodies, Vaccines
    and Therapeutic Antibodies Pipeline, 2011
  •   Prostate Cancer Vaccines and Therapeutic
    Antibodies Pipeline, 2011
  •   Breast Cancer Vaccines and Therapeutic
    Antibodies Pipeline, 2011
  •   Alzheimers Disease Biomarkers in Cerebrospinal
    Fluid and Blood, 2011
  •   Image-Based Biomarkers in Alzheimers Disease,
    2011
  •   Lung Cancer Vaccines and Therapeutic
    Antibodies Pipeline, Strategies and Clinical

5
For More details
  • http//www.aarkstore.com/reports/Alzheimers-Diseas
    e-Biomarkers-in-Cerebrospinal-Fluid-and-Blood-2011
    -146443.html
  • Vina
  • Aarkstore.com
  • Contact Marketing team
  • Mob.No.918149852585
  • Email enquiry_at_aarkstore.com
  • URL http//www.aarkstore.com/
  • XML http//www.aarkstore.com/feeds/Biopharmrepor
    ts.xml
About PowerShow.com